Amgen Fraud Suit to Proceed as Class-Action

The U.S. Supreme Court shot down an effort by Epogen-maker Amgen to disqualify a securities fraud case as a class-action suit, sending the claims back to a lower court.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news